Status:
RECRUITING
A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A
Lead Sponsor:
Addpharma Inc.
Conditions:
Mixed Dyslipidemia
Eligibility:
All Genders
19+ years
Phase:
PHASE1
Brief Summary
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of PA-111 in healthy subjects.
Detailed Description
The purpose of this study is to evaluate the pharmacokinetic characteristics and safety profiles of PA-111 compared with coadministration PA-111A in healthy subjects.
Eligibility Criteria
Inclusion
- Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
- The Age equal to or greater than 19 in healthy volunteers at the time of screening visit
Exclusion
- Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
- Other exclusions applied
Key Trial Info
Start Date :
April 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2025
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT06932705
Start Date
April 1 2025
End Date
May 1 2025
Last Update
April 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
H Plus Yangji Hospital
Seoul, South Korea